What Is Dihexa? Definition and What Research Reports

Plain definition

Dihexa is the informal research name for a small synthetic molecule chemically described as N-hexanoic-Tyr-Ile-(6) aminohexanoic amide. It was designed as a simplified, more stable analog of angiotensin IV — a short fragment generated from the same peptide family as the blood-pressure hormone angiotensin II. In the laboratory literature it is usually discussed in one of two ways: as a ligand at the so-called AT4 site (now generally identified as the enzyme insulin-regulated aminopeptidase, or IRAP), and as a proposed potentiator of hepatocyte growth factor (HGF) signalling through its receptor c-Met. Dihexa is not an approved drug in any jurisdiction, is not a dietary supplement, and has no established human dosing. This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision.

What dihexa is in biochemical terms

Strictly speaking, dihexa is a peptidomimetic rather than a conventional peptide. Its core is a two-residue tyrosine–isoleucine motif borrowed from the N-terminal end of angiotensin IV, capped at one end with a hexanoic acid chain and extended at the other with a 6-aminohexanoic amide — the two "hexa" groups that give the nickname its shape. Those modifications were intended to reduce cleavage by peptidases and increase lipophilicity relative to the parent peptide, which is the standard medicinal-chemistry rationale for converting a short neuropeptide fragment into a longer-lived small molecule.

Two target systems anchor the term:

• IRAP / the AT4 site. Angiotensin IV binds insulin-regulated aminopeptidase, and IRAP has become a target of independent biochemical interest. Researchers described an improved recombinant expression and purification route for human IRAP specifically to enable biochemical and crystallography studies of the enzyme and its ligands (PMID 34169156). Separate work with the IRAP inhibitor C9 reported restoration of cellular activity in methadone-damaged primary cell cultures, illustrating how IRAP-directed compounds are tested in cell models (PMID 41077171).
• HGF and c-Met. Dihexa is frequently described in secondary sources as an HGF/c-Met potentiator. The published HGF-mimetic literature, however, mostly concerns other agents: a hepatocyte growth factor mimetic was reported to protect against aminoglycoside-induced hair cell death in vitro (PMID 37192594), and the HGF mimetic ANG-3777 was studied in cardiac surgery–associated acute kidney injury (PMID 33305126). Those papers define what an "HGF mimetic" means in practice; they are not studies of dihexa.

How the term is used in peptide research

Within the scientific literature, "dihexa" functions as a shorthand for a specific chemical entity in the angiotensin IV analog series. Papers in this field tend to use the term in three contexts:

1. As a member of the angiotensin IV analog family. The broader family is where most published evidence sits. In a mouse model of Alzheimer's disease, researchers reported that memory and cerebrovascular deficits recovered following angiotensin IV intervention (PMID 31669735). A 2024 study of an angiotensin IV analog examined 3-nitropropionic acid–induced Huntington's disease–like symptoms in rats (PMID 38489193).
2. As a probe of the AT4/IRAP binding site. Work on angiotensin IV receptors in the rat prefrontal cortex reported neuronal expression of the receptor and inhibition of NMDA-mediated signalling, which is one of the mechanistic threads used to explain why this peptide family is studied in learning and memory at all (PMID 39857655).
3. As a comparator in renin-angiotensin system cognition research. A review of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers examined reported cognitive-enhancing effects on learning and memory, situating angiotensin-derived compounds within a wider body of work on this hormone system and the brain (PMID 26069362).

Boundary conditions the literature has described

The angiotensin IV effect is not uniform across models. Researchers reported that low-dose chronic prenatal alcohol exposure abolished the pro-cognitive effects of angiotensin IV in one behavioural study (PMID 28457883), and a related paper described decreased behavioural and neurochemical effects of angiotensin IV following prenatal alcohol exposure in the mouse (PMID 31079845). Those findings matter definitionally: they show that outcomes attributed to this peptide class in the literature were model- and context-dependent rather than universal.

Where the term is misused

Several recurring errors appear when "dihexa" is discussed outside the primary literature:

• Treating animal or cell findings as human findings. The cognition-related studies in this family were conducted in rodents (PMID 31669735, PMID 38489193). Rodent behavioural outcomes do not translate automatically to people.
• Attributing angiotensin IV results to dihexa. Much of what circulates as "dihexa research" is actually work on angiotensin IV itself or on unrelated HGF mimetics such as ANG-3777 (PMID 33305126). The compounds are related by design logic, not identical.
• Calling it a peptide without qualification. It is a modified dipeptide-derived small molecule, which is why it is more accurately labelled a peptidomimetic.
• Implying regulatory approval. No approval exists. Material sold under the name is typically labelled research-use-only, a category reviewed in a 2026 overview of therapeutic peptides that discussed applications, challenges and translational gaps in the peptide field (PMID 41490200).
• Quoting precise human doses. No published human dose-finding trial of dihexa appears in the verified literature reviewed here, so any numeric human protocol circulating online has no citable source behind it.

Related terms

Safety and Risk Signals in the Literature: What Studies Report

There is no published human safety dataset for dihexa in the verified literature covered here, so the honest summary is that its adverse-event profile in people has not been characterised. Two indirect considerations appear in the surrounding science. First, HGF/c-Met is a growth-factor axis with roles in tissue repair and in tumour biology; one study reported that extracellular superoxide dismutase inhibited HGF-mediated breast cancer–fibroblast interactions, work that illustrates why HGF signalling is examined in cancer-relevant models as well as regenerative ones (PMID 29296173). Second, the angiotensin IV pathway intersects with NMDA-receptor signalling in cortical neurons, as researchers reported in the rat prefrontal cortex (PMID 39857655). Neither observation establishes harm or benefit for dihexa in humans; both simply mark the biological systems involved. Broader commentary on therapeutic peptides has emphasised manufacturing quality, characterisation and regulatory hurdles as ongoing challenges for the field (PMID 41490200).

How to read claims about dihexa

A practical reading checklist for anyone evaluating a claim: identify whether the cited study tested dihexa or a relative such as angiotensin IV, C9 or ANG-3777; note the species and whether the work was in vitro; and check whether the reported endpoint was a behavioural score, a cellular assay, or a clinical outcome. The clearest examples of each type in the verified literature are a cell-culture IRAP study (PMID 41077171), a rodent behavioural study (PMID 28457883), and a clinical HGF-mimetic study in kidney injury (PMID 33305126). Distinguishing those tiers prevents the most common category error in dihexa discussions.

References

• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions (JAAOS Global Research & Reviews, 2026)
• Insulin-regulated aminopeptidase inhibitor C9 restores cellular activity in methadone-damaged primary cell cultures (Neuroscience Letters, 2025)
• Hepatocyte Growth Factor Mimetic ANG-3777 for Cardiac Surgery-Associated Acute Kidney Injury (Kidney International Reports, 2020)
• Extracellular superoxide dismutase inhibits hepatocyte growth factor-mediated breast cancer-fibroblast interactions (Oncotarget, 2017)
• Angiotensin IV Receptors in the Rat Prefrontal Cortex: Neuronal Expression and NMDA Inhibition (Biomedicines, 2024)
• Effects of an Angiotensin IV Analog on 3-Nitropropionic Acid-Induced Huntington's Disease-Like Symptoms in Rats (Journal of Huntington's Disease, 2024)
• Hepatocyte growth factor mimetic confers protection from aminoglycoside-induced hair cell death in vitro (Hearing Research, 2023)
• Enhanced recombinant expression and purification of human IRAP for biochemical and crystallography studies (Biochemistry and Biophysics Reports, 2021)
• Decreased behavioural and neurochemical effects of angiotensin IV following prenatal alcohol exposure in the mouse (Neuropeptides, 2019)
• Low-dose chronic prenatal alcohol exposure abolishes the pro-cognitive effects of angiotensin IV (Behavioural Brain Research, 2017)
• Cognitive enhancing effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on learning and memory (Indian Journal of Pharmacology, 2015)
• Memory and cerebrovascular deficits recovered following angiotensin IV intervention in a mouse model of Alzheimer's disease (Neurobiology of Disease, 2020)